Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Emergent BioSolutions Q2 Adj. EPS $0.16 Beats $(0.72) Estimate, Sales $140.90M Beat $105.00M Estimate

Author: Benzinga Newsdesk | August 06, 2025 04:15pm
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $(0.72) by 122.22 percent. This is a 106.9 percent increase over losses of $(2.32) per share from the same period last year. The company reported quarterly sales of $140.90 million which beat the analyst consensus estimate of $105.00 million by 34.19 percent. This is a 44.68 percent decrease over sales of $254.70 million the same period last year.

Posted In: EBS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist